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eHôpital Bich
fBrigham and
Medical Schoo
versity, Frank
tional GmbH,
Weimar (Lahn
Centre for Car
Heart and C
0002-9149/© 2
license. (http:/
https://doi.org/on the Efficacy and Safety of Dual Therapy
(Dabigatran + Clopidogrel or Ticagrelor) Versus Triple
Therapy (Warfarin + Aspirin + Clopidogrel or
Ticagrelor) in Patients With Atrial Fibrillation
After Percutaneous Coronary Intervention
(from the RE-DUAL PCI Trial)Jurrien M. ten Berg, MD, PhDa,*, Philippe Gabriel Steg, MDb,c,d,e, Deepak L. Bhatt, MD, MPHf,
Stefan H. Hohnloser, MDg, Anne de Veer, MDa, Matias Nordaby, MDh, Corinna Miede, MSci,
Takeshi Kimura, MD, PhDj, Gregory Y.H. Lip, MDk,l, Jonas Oldgren, MD, PhDm, and
Christopher P. Cannon, MDf, on behalf of the RE-DUAL PCI Steering Committee and Investigatorsus Z
iov
Pa
at,
Wo
l, B
furt
Ing
), G
diov
hes
019
/cre
10.The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily,
plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (war-
farin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who under-
went percutaneous coronary intervention, with noninferiority in composite thromboembolic
events. In this prespecified analysis, risks of first major or clinically relevant nonmajor
bleeding event and composite end point of death, thromboembolic events, or unplanned
revascularization were compared between dabigatran dual therapy and warfarin triple ther-
apy in older (≥ 75 years) and younger (< 75 years) patients, using Cox proportional hazard
regression. Of 2,725 patients randomized to treatment, 1,026 (37.7%) were categorized into
older and 1,699 (62.3%) into younger age groups. Dabigatran 110 mg dual therapy lowered
bleeding risk versus warfarin triple therapy in older (hazard ratio [HR] 0.67; 95% confi-
dence interval [CI] 0.51 to 0.89) and younger patients (HR 0.40; 95% CI 0.30 to 0.54); inter-
action p value: 0.0125. Dabigatran 150 mg dual therapy lowered bleeding risk versus
warfarin triple therapy in younger patients (HR 0.57; 95% CI 0.44 to 0.74), whereas no ben-
efit could be observed in older patients (HR 1.21; 95% CI 0.83 to 1.77); interaction p value:
0.0013. For the thromboembolic end point, there was a trend for a higher risk with dabiga-
tran 110 mg dual therapy in older patients, compared with warfarin triple therapy, whereas
the risk was similar in younger patients. For dabigatran 150 mg dual therapy, the thrombo-
embolic risk versus warfarin triple therapy was similar in older and younger patients. In
conclusion, the benefits of dabigatran dual therapy differed in the 2 age groups, which may
help dose selection when using dabigatran dual therapy. © 2019 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://
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1016/j.amjcard.2019.11.029Dabigatran is approved at 110 or 150 mg twice daily doses
for the prevention of stroke in atrial fibrillation (AF).1
The RE-DUAL PCI trial compared dabigatran dual therapy
(110 or 150 mg twice daily, plus clopidogrel or ticagrelor)
versus warfarin triple therapy (warfarin with aspirin plusclopidogrel or ticagrelor) in patients with AF who underwent
percutaneous coronary intervention (PCI).2 Dabigatran dual
therapy at both doses reduced the risk of bleeding—assessed
by International Society on Thrombosis and Haemostasis
(ISTH) major bleeding events (MBEs) or clinically relevant
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Figure 1. Patient randomization according to age group.
*For the comparison with dabigatran 150 mg dual therapy, elderly patients outside the United States aged ≥ 80 years (≥ 70 years in Japan) were excluded.
DE = dabigatran.
736 The American Journal of Cardiology (www.ajconline.org)nonmajor bleeding events (CRNMBEs)—compared with
warfarin triple therapy, and was noninferior for the composite
efficacy end point of thromboembolic events (myocardial
infarction, stroke, or systemic embolism), death, or unplanned
revascularization. The prevalence of AF is increased in older
patients due to aging and common predisposing co-morbid-
ities. In this prespecified analysis, we evaluated the influence
of patient age on the outcomes in the RE-DUAL PCI trial,
using age group as an exploratory variable in an unstratified
model, whereas in the main RE-DUAL PCI trial, age was
used as a stratifying factor.Table 1
Baseline characteristics according to age groups
Variable Age (yrs)
(≥ 75 years) (< 75 years)
Total (n = 1,026) Total (n = 1,699)
Mean age (yrs, § SD) 79.3 § 3.6 65.6 § 6.5
Men 704 (68.6%) 1366 (80.4%)
CHA2DS2-VASc* score
Mean § SD 4.6 § 1.3 3.0 § 1.4
0 0 32 (1.9%)
1 0 171 (10.1%)
2 38 (3.7%) 429 (25.3%)
> 2 988 (96.3%) 1,067 (62.8%)
Modified HAS-BLEDy score
Mean § SD 3.0 § 0.6 2.5 § 0.7
< 3 151 (14.7%) 792 (46.6%)
≥ 3 875 (85.3%) 907 (53.4%)
Diabetes mellitusz 343 (33.4%) 650 (38.3%)
Previous strokez 103 (10.0%) 123 (7.2%)
Previous percutaneous
coronary interventionz
337 (32.8%) 575 (33.8%)
Previous stent thrombosisx 24 (2.3%) 44 (2.6%)
Previous coronary artery diseasez 692 (67.4%) 1136 (66.9%)
Previous myocardial infarction 247 (24.1%) 452 (26.6%)
Previous coronary artery bypass graftz 117 (11.4%) 170 (10.0%)
Previous pulmonary embolism|| 16 (1.6%) 20 (1.2%)
Previous systemic embolismz 7 (0.7%) 14 (0.8%)
SD = standard deviation.
* The CHA2DS2-VASc score reflects the risk of stroke, with values rang-
ing from 0 to 9 and higher scores indicating greater risk.
yThe HAS-BLED score reflects the risk of major bleeding in patients
with atrial fibrillation who are receiving anticoagulant therapy, with values
ranging from 0 to 9 and with higher scores indicating greater risk.
zData missing from 1 younger patient.
xData missing from 15 older and 29 younger patients.
|| Data missing from 3 older and 5 younger patients.Methods
The design of the RE-DUAL PCI trial (NCT02164864)
has been reported previously.3 In brief, 2,725 patients aged
≥ 18 years with nonvalvular AF who underwent PCI for
acute coronary syndrome or stable coronary artery disease
were randomly assigned to dabigatran dual or warfarin tri-
ple therapy, with a mean follow-up of 14 months. Aspirin
was used for 1 month when a bare-metal stent was used,
and for 3 months when a drug-eluting stent was used.
Dabigatran 150 mg is not licensed in patients aged
≥ 80 years in Europe or ≥ 70 years in Japan, whereas dabi-
gatran at both 110- and 150-mg doses is approved in the
United States regardless of age. Elderly patients in non-US
countries (≥ 80 years) or Japan (≥ 70 years) were random-
ized in RE-DUAL PCI to receive dabigatran 110 mg dual
or warfarin triple therapy in a 1:1 ratio, whereas younger
patients in non-US countries (< 80 years) and Japan (< 70
years), and all US patients irrespective of age, were ran-
domized to dabigatran 110 mg dual, dabigatran 150 mg
dual, or warfarin triple therapy in a 1:1:1 ratio.
The primary safety end point in RE-DUAL PCI was the
time to first ISTH MBE/CRNMBE. Key efficacy end point
was a composite of the time to death, first thromboembolic
event, or unplanned revascularization. The current analysis
assessed these end points in patients categorized into older
(≥ 75 years) and younger (< 75 years) age groups.
Cox proportional hazard regression models were used to
compare dabigatran 110 or 150 mg dual versus warfarin tri-
ple therapy in older and younger age groups. Exploratory
treatment-by-subgroup interaction p values were provided
from the Cox proportional hazard regression models
(p <0.05 was considered statistically significant). Further-
more, the effect of age on the risk of the primary safety end
point and of the key composite efficacy end point was
investigated with a multivariable Cox proportional hazard
regression model that included treatment and age as acontinuous variable, as well as the interaction between
treatment and age. The resulting hazard ratios (HRs) and
confidence intervals (CIs) comparing dabigatran 110 or
150 mg dual versus warfarin triple therapy for varying val-
ues of age were visualized via interaction plots.Results
Of the 2,725 patients randomized to treatment, 1,026
(37.7%) were categorized into older and 1,699 (62.3%) into
younger age groups (Figure 1). Baseline characteristics of
older and younger patients are shown in Table 1. Compared
with younger patients, older patients were at higher risk of
Figure 2. Outcomes in older and younger patients according to treatment: dabigatran 110 mg dual therapy.
Patients aged ≥ 80 years outside the United States and patients aged ≥ 70 years from Japan were assigned to either DE 110 mg or warfarin in a 1:1 ratio; all
other patients are randomized to all 3 treatment groups in a 1:1:1 ratio. HRs and 95% CIs from Cox proportional hazard models. CI = confidence interval;
CRNMBE = clinically relevant nonmajor bleeding event; DE = dabigatran etexilate; DTE = death or thromboembolic event; HR = hazard ratio; ISTH = Inter-
national Society on Thrombosis and Haemostasis; MBE =major bleeding event.
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broadly similar.
Dabigatran 110 mg dual therapy lowered the risk of MBE/
CRNMBE versus warfarin triple therapy in older patients
(HR 0.67; 95% CI 0.51 to 0.89) and younger patients
(HR 0.40; 95% CI 0.30 to 0.54; Figures 2 and 3). Younger
patients seem to be favored even more with respect to MBE/
CRNMBE by the 110 mg dabigatran dose than older patients,
as suggested by the significant interaction p value (0.013;
Figure 2). Dabigatran 150 mg dual therapy lowered the risk
of MBE/CRNMBE versus warfarin triple therapy in younger
patients (HR 0.57; 95% CI 0.44 to 0.74), whereas no benefit
could be observed in older patients (HR 1.21; 95% CI 0.83 to
1.77; interaction p value: 0.001; Figures 4 and 5). A reliable
conclusion is however difficult, because the number of older
patients with dabigatran 150 mg dual therapy is low.
For the thromboembolic end point, there was a trend of a
higher risk with dabigatran 110 mg dual therapy in older
patients compared with warfarin triple therapy (HR 1.54;
95% CI 1.07 to 2.22), whereas the risk was similar to warfa-
rin triple therapy in younger patients (HR 0.90; 95% CI 0.66
to 1.23; Figures 2 and 3). Thus, older patients seem to be less
protected for thromboembolic events by the dabigatran
110 mg dose than younger patients, as is suggested by the
significant interaction p value (0.029; Figure 2). For dabiga-
tran 150 mg dual therapy, the thromboembolic risk versus
warfarin triple therapy was similar in older (HR 1.34; 95%
CI 0.73 to 2.44) and younger patients (HR 0.79; 95% CI 0.57
to 1.09; interaction p value: 0.129; Figures 4 and 5). A reli-
able conclusion is however difficult, because the number of
older patients with dabigatran 150 mg dual therapy is low.
The interaction plots displaying the HRs and 95% CIs in
the comparison of dabigatran 110 mg dual therapy versus
warfarin triple therapy and dabigatran 150 mg dual therapy
versus warfarin triple therapy are shown in Figures 6 and 7.
They mainly support the results as obtained from the sub-
group analysis. However, in contrast to the subgroup analy-
sis with age as a categorical variable, the interaction
p value from the model considering age as a continuousvariable was statistically not significant (0.219) when com-
paring the efficacy between dabigatran 110 mg dual therapy
and warfarin triple therapy.Discussion
Because older patients have an increased risk both for
bleeding and for thromboembolic events compared with
younger patients, we analyzed whether the observed reduc-
tion of bleeding and similar thromboembolic risk with the
use of dabigatran dual therapy compared with warfarin tri-
ple therapy observed in RE-DUAL PCI was the same in
older (≥ 75 years of age) and in younger (< 75) patients.
The most important findings of this analysis were: (1) both
older and younger patients had a lower risk of bleeding
with dabigatran 110 mg dual therapy than with warfarin tri-
ple therapy; (2) in younger patients treated with dabigatran
110 mg dual therapy, the risk of the thromboembolic end
point was similar to that of patients treated with warfarin tri-
ple therapy, whereas in older patients, the risk tended to be
higher for patients treated with dabigatran dual therapy; (3)
the benefit of dabigatran 150 mg dual therapy with regard to
bleeding risk was observed only in younger patients, whereas
the results suggest no benefit in older patients; (4) the risk of
the thromboembolic end point with dabigatran 150 mg dual
versus warfarin triple therapy was similar in older and youn-
ger patients; (5) a reliable conclusion for older patients
treated with dabigatran 150 mg dual versus warfarin triple
therapy is difficult because of the low numbers.
There is a paucity of published data to guide anticoagu-
lation regimens in older patients with AF who underwent
PCI. Neither the WOEST, PIONEER-PCI, nor AUGUS-
TUS trials reported comparative outcomes in different age
groups.4−6 Subgroup analysis of the RE-LY trial based on
age category showed that dabigatran at 110 and 150 mg
twice daily doses was associated with lower risks of intra-
cranial and extracranial bleeding compared with warfarin in
younger patients (age <75 years), whereas older patients
had a lower risk of intracranial bleeding and a similar or
Figure 3. Kaplan-Meier analysis for (A) time to first adjudicated ISTH MBE or CRNMBE and (B) DTE or unplanned revascularization (intent to treat period)
by age group: dabigatran 110 mg dual therapy.
CRNMBE = clinically relevant nonmajor bleeding event; DE = dabigatran etexilate; DTE = death or thromboembolic event; ISTH = International Society on
Thrombosis and Haemostasis; MBE =major bleeding event.
738 The American Journal of Cardiology (www.ajconline.org)higher risk of extracranial bleeding with dabigatran than
warfarin, the latter potentially attributable to a combination
of age-related factors such as decreased renal excretion and
increased prevalence of gastrointestinal pathology and
pharmacokinetic interactions.7 Our analysis also shows dif-
ferent outcomes in elderly patients compared with younger
patients. For the 110-mg dabigatran dose (when combined
with clopidogrel or ticagrelor), the results suggest that it is
less effective in preventing thromboembolism in olderpatients compared with younger patients. For the 150-mg
dabigatran dose (combined with clopidogrel or ticagrelor),
the results suggest that there is no reduced bleeding risk in
older patients compared with warfarin triple therapy which
was observed in younger patients. The same factors
observed in the RE-LY trial explaining the different effects
of dabigatran in elderly patients may apply to this analysis.
A limitation of our current analysis is that, as a subgroup
analysis of the RE-DUAL PCI trial, it was not powered for
Figure 4. Outcomes in older and younger patients according to treatment: dabigatran 150 mg dual therapy.
Patients aged ≥ 80 years outside the United States and patients aged ≥ 70 years from Japan were assigned to either DE 110 mg or warfarin in a 1:1 ratio; all
other patients are randomized to all 3 treatment groups in a 1:1:1 ratio. *For the comparison with dabigatran 150 mg dual therapy, elderly patients outside the
United States aged ≥ 80 years (≥ 70 years in Japan) are excluded. HRs and 95% CIs from Cox proportional hazard models. CI = confidence interval;
CRNMBE = clinically relevant nonmajor bleeding event; DE = dabigatran etexilate; DTE = death or thromboembolic event; HR = hazard ratio; ISTH = Inter-
national Society on Thrombosis and Haemostasis; MBE =major bleeding event.
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DUAL PCI patient cohort, and the fact that outcomes data
were prospectively collected and adjudicated, alleviate this
limitation to an extent, but for the low number of older
patients treated with dabigatran 150 mg dual therapy, a reli-
able conclusion is difficult.
In conclusion, dabigatran 110 mg dual therapy provided
a consistent reduction in bleeding risk compared with war-
farin triple therapy in both older and younger patients. The
risk for the thromboembolic end point appeared to be higher
in older patients with dabigatran 110 mg dual therapy ver-
sus warfarin triple therapy but the risk was similar in youn-
ger patients. Dabigatran 150 mg dual therapy lowered
bleeding risk compared with warfarin triple therapy in
younger patients, whereas the benefit for risk of bleeding in
older patients could not be observed. For the thromboem-
bolic end point, the results suggest similar risks with dabi-
gatran 150 mg dual therapy as for warfarin triple therapy in
both older and younger patients. In conclusion, the benefits
of dabigatran dual therapy differed in the 2 age groups,
which may help dose selection when using dabigatran dual
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